PRA Health Sciences’ Early Patient Solutions (EPS) is an established team of highly experienced Phase I professionals dedicated to early phase patient trials. PRA’s EPS team has successfully managed more than 50 hepatic impairment studies, bringing the same efficiency and rigor you’ve come to expect in our Phase I trial oversight. Hepatic impairment trials are often critical for meeting submission timelines or supporting pivotal studies, which is why our team assesses each project to employ the best solution to achieve your objectives. Our EPS team benefits from a network of highly experienced hepatic sites in both Europe and the United States, including PRA-owned clinics with access to hepatic impaired patients, leading to proven and predictable enrollment. PRA offers trial design, conduct oversight, regulatory support, GMP support, biometrics, and medical and clinical monitoring for comprehensive and seamless support of hepatic impairment trials.
Chemical, Manufacturing, and Control Services (CMC)
Early drug development requires manufacturing of Investigational Medicinal Products (IMP) that comply with Good Manufacturing Practice (GMP) systems…
Phase I healthy volunteer studies play a vital role in clinical research by providing researchers with the knowledge they need to make educated…
Early Patient Solutions
We provide the infrastructure, technologies, and expertise required to execute early phase patient studies worldwide.